Menu
MorphoSys US

MorphoSys'
therapeutic pipeline

You are here

  1. Home
  2. Pipeline
  3. Pipeline

With currently more than 100 distinct drugs in research and development, MorphoSys has one of the broadest pipelines in the biotechnology industry, including unique approaches that aim to help patients with conditions such as cancer, Alzheimer’s disease, infectious diseases, cardiovascular dysfunction and inflammation.

More than 20 therapeutic antibodies are being evaluated by MorphoSys and its partners in clinical trials as potentially novel treatment options for severe and in many cases life-threatening diseases. Several of these in-house and partnered programs have already demonstrated initial potential for diseases where currently no proper treatment is available.
MorphoSys continues to expand its portfolio of unique drug candidates and is looking for partners with innovative targets, supportive technologies and promising antibodies for further development.

 

Clinical Pipeline

  • Proprietary Development Programs
  • Partnered Discovery Programs
  • Phase 1
  • Phase 2
  • Phase 3
  • Market
28 Antibodies available:
Program
Partner
Indication
Phase

Tafasitamab-cxix (MOR208)

Partner

Incyte Corporation*

Indication

Phase

Relapsed or refractory diffuse large B cell lymphoma (DLBCL) (L-MIND) (Monjuvi® - U.S. only – accelerated approval)
Phase 1 Phase 2 Phase 3 Market (Current Phase)
Relapsed or refractory diffuse large B cell lymphoma (DLBCL) (B-MIND)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) (COSMOS)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Relapsed or refractory diffuse large B cell lymphoma (DLBCL) (L-MIND)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Diffuse large B cell lymphoma (DLBCL) (First-MIND)
Phase 1 (Current Phase) Phase 2 Phase 3 Market

*Global Collaboration and License Agreement with Incyte Corporation; co-commercialization in the U.S.; Incyte has exclusive commercialization rights outside the U.S.

  • MOR208 (former XmAb®5574)
  • INN: tafasitamab
  • Target: CD19
More Information on Tafasitamab (MOR208)

Felzartamab (MOR202)

Partner

I-Mab Biopharma*

Indication

Phase

Multiple myeloma (MM) (combo with lenalidomide)*
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Multiple myeloma (MM)*
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Anti-PLA2R-positive membranous nephropathy (M-PLACE)
Phase 1 (Current Phase) Phase 2 Phase 3 Market

* Felzartamab (MOR202/TJ202): Sublicensed to I-Mab for development in China, Hong Kong, Macao and Taiwan.

  • A fully human HuCAL antibody
  • Target: CD38
More Information on Felzartamab (MOR202)

Otilimab (MOR103/GSK3196165)

Partner

GlaxoSmithKline*

Indication

Phase

Rheumatoid arthritis (ContRAst1)*
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Rheumatoid arthritis (ContRAst2)*
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Rheumatoid arthritis (ContRAst3)*
Phase 1 Phase 2 Phase 3 (Current Phase) Market

*Fully outlicensed to GlaxoSmithKline.

  • A fully human HuCAL antibody
  • Target: GM-CSF
More Information on otilimab (MOR103/GSK3196165)

Tremfya® (guselkumab)

Partner

Janssen/J&J

Indication

Phase

Plaque psoriasis
Phase 1 Phase 2 Phase 3 Market (Current Phase)
Psoriatic arthitis (PsA)
Phase 1 Phase 2 Phase 3 Market (Current Phase)
Palmoplantar pustolosis (Japan only)
Phase 1 Phase 2 Phase 3 Market (Current Phase)
Plaque psoriasis (GUIDE)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Psoriatic arthritis (PsA) (COSMOS)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Psoriatic arthritis (PsA)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Palmoplantar-non-pustular psoriasis (G-PLUS)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Chronic plaque psoriasis (pediatric participants) (PROTOSTAR)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Crohn's disease
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Crohn's disease (GALAXI)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Ulcerative colitis (QUASAR)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Ulcerative colitis (VEGA)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Hidradenitis suppurativa (HS) (NOVA)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Pityriasis rubra pilaris
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Familial adenomatous polyposis
Phase 1 (Current Phase) Phase 2 Phase 3 Market
  • A fully human HuCAL antibody
  • Target: IL23p19
  • Aliases: CNTO1959

Additional Information:

More Information on Guselkumab

Gantenerumab

Partner

Roche

Indication

Phase

Early Alzheimer's disease (GRADUATE-1)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Early Alzheimer's disease (GRADUATE-2)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Mild Alzheimer's disease (Marguerite RoAD) (OLE)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Prodromal Alzheimer's disease (Scarlett RoAD) (OLE)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Rollover study on long-term administration of gantenerumab
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Genetically predisposed for Alzheimer's disease (DIAN)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Alzheimer's disease (Brain Shuttle Gantenerumab, RG6102)
Phase 1 (Current Phase) Phase 2 Phase 3 Market
  • A fully human HuCAL antibody
  • Target: Amyloid-beta

Additional Information:

Anetumab Ravtansine

Partner

Bayer AG

Indication

Phase

  • A fully human HuCAL-based antibody drug conjugate (ADC)
  • Target: Mesothelin
  • Alias: BAY94-9343​

Additional Information:

Anetumab ravtansine

Partner

Bayer AG

Indication

Phase

Mesothelioma
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Cancer, multi-indications
Phase 1 (Current Phase) Phase 2 Phase 3 Market
  • A fully human HuCAL-based antibody drug conjugate
  • Target: Mesothelin
  • Alias: BAY94-9343​

Additional Information:

BHQ880

Partner

Novartis

Indication

Phase

Multiple myeloma (MM)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
  • A fully human HuCAL antibody
  • Target: DKK-1

Additional Information:

Bimagrumab

Partner

Novartis

Indication

Phase

Type 2 diabetes
Phase 1 Phase 2 (Current Phase) Phase 3 Market
  • A fully human HuCAL antibody 
  • Target: ActRIIB
  • Aliases: BYM338

Additional information:

FTC001 (CNTO6785)

Partner

J&J/Shandong Fontacea

Indication

Phase

Inflammation
Phase 1 Phase 2 (Current Phase) Phase 3 Market
  • A fully human HuCAL antibody

*For development in China, Hong Kong, Taiwan, Macao & South Korea.

Additional Information:

Ianalumab (VAY736)

Partner

Novartis

Indication

Phase

ADCC mediated B cell depletion & BAFF-R blockade (AMBER)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Pemphigus vulgaris
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Idiopathic pulmonary fibrosis
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Primary Sjögren's syndrome (efficacy & safety)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Systemic Lupus Erythematosus (SLE)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Chronic lymphocytic leukemia (combo with ibrutinib)
Phase 1 (Current Phase) Phase 2 Phase 3 Market
Rheumatoid arthritis (RA)
Phase 1 (Current Phase) Phase 2 Phase 3 Market
  • A fully human HuCAL antibody 
  • Target: BAFF-R

Additional information:

Setrusumab (BPS804)

Partner

Novartis/Mereo

Indication

Phase

Brittle bone disease (Type I, III, IV) (ASTEROID)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
  • A fully human HuCAL antibody 
  • Target: Sclerostin

Additional information:

Tesidolumab (LFG316)

Partner

Novartis

Indication

Phase

Paroxysmal nocturnal hemoglobinuria
Phase 1 Phase 2 (Current Phase) Phase 3 Market
  • A fully human HuCAL antibody 
  • Target: C5

Additional Information:

Utomilumab (PF-05082566)

Partner

Pfizer

Indication

Phase

Breast cancer (AVIATOR)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Breast cancer (combo with avelumab) (InCITe)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Solid tumors (combo with ISA101b vaccination)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Advanced Malignancies (combo with avelumab, PF-04518600 & CMP-001 (TLR9 agonist)) (JAVELIN Medley)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Advanced malignancies (combo with avelumab & PF-04518600)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Refractory large B cell lymphoma (combo with Axicabtagene ciloleucel) (ZUMA-11)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Colorectal cancer (combo with cetuximab & irinotecan)
Phase 1 (Current Phase) Phase 2 Phase 3 Market
Advanced ovarian cancer (T cell immunotherapy)
Phase 1 (Current Phase) Phase 2 Phase 3 Market
r/r DLBCL & MCL (avelumab plus utomilumab-based combination therapy)
Phase 1 (Current Phase) Phase 2 Phase 3 Market
Breast cancer (combo with trastuzumab emtansine or trastuzumab)
Phase 1 (Current Phase) Phase 2 Phase 3 Market
Follicular lymphoma (combo with rituximab, avelumab und PF04518600)
Phase 1 (Current Phase) Phase 2 Phase 3 Market
  • A fully human HuCAL antibody
  • Target: 4-1BB (CD137)
  • Alias: PF-05082566

Additional Information:

Xentuzumab (BI-836845)

Partner

Boehringer Ingelheim

Indication

Phase

Breast cancer
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Castration-resistant prostate cancer (CRPC) (combo with enzalutamide)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Solid tumors (Japan)
Phase 1 (Current Phase) Phase 2 Phase 3 Market
Solid tumors (combo with abemaciclib)
Phase 1 (Current Phase) Phase 2 Phase 3 Market
EGFR mutant non-small cell lung cancer (NSCLC)
Phase 1 (Current Phase) Phase 2 Phase 3 Market
  • A fully human HuCAL antibody
  • Target: IGF-1

Additional Information:

CNTO3157

Partner

Janssen/J&J

Indication

Phase

Inflammation
Phase 1 (Current Phase) Phase 2 Phase 3 Market
  • A fully human HuCAL antibody

Additional Information:

Elgemtumab (LJM716)

Partner

Novartis

Indication

Phase

HER2+ cancer (combo with BYL719 & trastuzumab)
Phase 1 (Current Phase) Phase 2 Phase 3 Market
  • A fully human HuCAL antibody
  • Target: HER3

Additional information:

NOV-11

Partner

Novartis

Indication

Phase

Blood disorders
Phase 1 (Current Phase) Phase 2 Phase 3 Market

NOV-15

Partner

Novartis

Indication

Phase

Undisclosed
Phase 1 (Current Phase) Phase 2 Phase 3 Market

Vantictumab (OMP-18R5)

Partner

Mereo

Indication

Phase

Cancer
Phase 1 (Current Phase) Phase 2 Phase 3 Market
  • A fully human HuCAL antibody
  • Target: Wnt signaling pathway (Fzd 7)
  • Alias: OMP-18R5

Additional information:

* Tafasitamab: Global Collaboration and License Agreement with Incyte Corporation; co-commercialization in the U.S.; Incyte has exclusive commercialization rights outside the U.S.
* Felzartamab (MOR202): Sublicensed to I-Mab for development in China, Hong Kong, Macao and Taiwan.
* Otilimab: Fully outlicensed to GlaxoSmithKline.

Physicians and Patients

Physicians interested in learning more about MorphoSys-sponsored clinical trials should contact: medical@morphosys.com.

Patients are kindly asked to contact their treating physicians if they are interested in participating in any of MorphoSys's clinical trials.

Disclaimer
MorphoSys’s product candidates are investigational and are currently not approved for the treatment of any disease or condition anywhere in the world. They cannot be prescribed or purchased for therapy at present.
The MorphoSys website may contain information on drug candidates and clinical trials sponsored by MorphoSys with the intention of increasing the transparency of the company’s clinical research. There is no guarantee any product will be approved in the sought after indication.
Information contained within this website is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before making any decisions on their treatment.
All reasonable precautions have been taken to ensure the accuracy, security and confidentiality of information available through the site. MorphoSys may amend the information at any time without notice.

You are leaving morphosys.com and will be transferred to the MorphoSys US website which is intended for US residents.

Do you wish to proceed?

Yes No